Neumora goes big with three PhIII depression studies, new CEO from AbbVie’s C-suite
The wheels are rolling fast at Neumora as the “Really Big Neuroscience Company” nears three Phase III trials for its investigational depression drug, readies a slate of other clinical studies and woos a new CEO from Big Pharma.
Neumora said Tuesday morning it hired Henry Gosebruch as president and CEO. Gosebruch, AbbVie’s former chief strategy officer, joined July 3 and takes the place of Paul Berns, who transitioned to executive chair.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.